Umbilical cord stem cell-derived exosome liquid "Prosentan"
(1) Treatment details: Stem cell-derived exosomes will be administered to patients by inhalation, application, subcutaneous injection, intravenous injection, intramuscular injection, etc., and various effects are expected.
(2) Prescriptionable drugs and fees: Stem cell acclimatization culture solution (price: 280,000 yen for 1 box of 10 bottles)
(3) Main side effects and risks: Minor symptoms such as itching, rash, slight fever, and allergic reactions may occur in rare cases.
(4) Clarification that it is an unapproved drug: This drug is an unapproved drug in Japan and will be prescribed at your own expense.
*Public relief systems (relief system for victims of adverse drug reactions, relief system for victims of biological product infections, etc.) are not applicable to unapproved drugs.
Thank you for your understanding.
(5) Clarification of route of acquisition: This drug is an in-hospital preparation.
(6) Existence of domestically approved drugs with the same ingredients and efficacy: None
(7) Disclosure of information related to safety in other countries: Same as the safety of exosome therapy. No major adverse events were reported.
Stem cell administration treatment (intravenous administration/subcutaneous)
(1) Details of treatment: Autologous stem cells will be cultured in an in-hospital CPC and administered to patients via intravenous, subcutaneous, intramuscular, or intraarticular injections, with the hope of producing tissue regeneration effects.
(2) Prescriptionable drugs and fees: Stem cells (prices vary depending on the number of cells)
(3) Main side effects and risks: Minor symptoms such as itching, rash, slight fever, and allergic reactions may occur in rare cases.
(4) Clarification that it is an unapproved drug: This treatment is an unapproved drug in Japan and will be prescribed at your own expense.
*Public relief systems (relief system for victims of adverse drug reactions, relief system for victims of biological product infections, etc.) are not applicable to unapproved drugs.
Thank you for your understanding.
(5) Clarification of route of acquisition, etc.: This drug is manufactured at the in-hospital CPC.
(6) Existence of domestically approved drugs with the same ingredients and efficacy: None
(7) Disclosure of information related to safety in other countries: Same as the safety of stem cell therapy. No major adverse events were reported.
Stem cell administration treatment (intra-articular)
(1) Treatment details: Autologous stem cells are cultured in the in-hospital CPC and administered to the patient via intra-articular administration, in hopes of regenerating tissue within the joint.
(2) Prescriptionable drugs and fees: Stem cells (prices vary depending on the number of cells)
(3) Main side effects and risks: Minor symptoms such as itching, rash, slight fever, and allergic reactions may occur in rare cases.
(4) Clarification that it is an unapproved drug: This treatment is an unapproved drug in Japan and will be prescribed at your own expense.
*Public relief systems (relief system for victims of adverse drug reactions, relief system for victims of biological product infections, etc.) are not applicable to unapproved drugs.
Thank you for your understanding.
(5) Clarification of route of acquisition, etc.: This drug is manufactured at the in-hospital CPC.
(6) Existence of domestically approved drugs with the same ingredients and efficacy: None
(7) Disclosure of information related to safety in other countries: Same as the safety of stem cell therapy. No major adverse events were reported.
Stem cell administration treatment (periodontal disease)
(1) Treatment details: Autologous stem cells will be cultured in an in-hospital CPC and administered to patients through methods such as gingival injection, in hopes of regenerating surrounding tissue.
(2) Prescriptionable drugs and fees: Stem cells (prices vary depending on the number of cells)
(3) Main side effects and risks: Minor symptoms such as itching, rash, slight fever, and allergic reactions may occur in rare cases.
(4) Clarification that it is an unapproved drug: This treatment is an unapproved drug in Japan and will be prescribed at your own expense.
*Public relief systems (relief system for victims of adverse drug reactions, relief system for victims of biological product infections, etc.) are not applicable to unapproved drugs.
Thank you for your understanding.
(5) Clarification of route of acquisition, etc.: This drug is manufactured at the in-hospital CPC.
(6) Existence of domestically approved drugs with the same ingredients and efficacy: None
(7) Disclosure of information related to safety in other countries: Same as the safety of stem cell therapy. No major adverse events were reported.
About medical advertising guidelines
In response to the medical advertising guidelines that came into effect on June 1, 2018, the HELENE Group has deleted testimonials from its website. In addition, when posting case photos, we have completely revised the website so that the explanation of the treatment, the risks of the treatment, and the price of the treatment are also displayed.
We apologize for any inconvenience caused to patients and customers viewing this website, but we appreciate your understanding.
Partial excerpt from the original medical advertising guidelines
Part 1 Purpose of Advertising Regulations
Partial revision of the Medical Care Act
As with other advertising media, limiting the items that can be advertised on the websites of medical institutions, etc. may hinder the smooth provision of information requested by patients, such as detailed medical treatment content. Under certain conditions, restrictions on items that can be advertised will be lifted.
Section 3 Prohibited Advertisements
(5) Testimonials regarding the contents or effects of treatments, etc., based on subjective opinions of patients, etc.
Article 1-9, Item 1 of the Ministerial Ordinance stipulates that "not to advertise patient's or other person's subjective experiences or testimonials based on hearsay." Refers to subjective testimonials based on one's own experiences or hearsay from family members, etc., for the purpose of attracting patients to the medical institution concerned. The impression will naturally differ depending on the person, and it is not acceptable as an advertisement related to medical care, given that there is a risk of misleading.
(6) Photographs, etc. before or after treatment, etc. that may mislead the patient, etc. as to the content or effect of the treatment, etc.
Article 1-9, Item 2 of the Ministerial Ordinance stipulates that “not to advertise before or after treatment, etc. that may mislead patients, etc. about the content or effect of treatment, etc.” This refers to so-called before-after photographs, etc. However, given that the results of treatment, etc., naturally differ depending on the conditions of individual patients, photographs, etc. that may mislead patients are not permitted as medical advertisements. be something that cannot be
In addition, this does not apply to the case where detailed explanations such as matters related to treatment contents, costs, etc., which are usually required for pre-operative or post-operative photographs, matters related to main risks of treatment, etc., side effects, etc. are attached. Being a thing.
Furthermore, in regard to the location of the information, sufficient consideration should be given to make it easy for patients, etc. to understand. Do not adopt a format such as
